MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting Reuters Synergistic Effects Seen with Four Approved Treatment Options Including Rituximab and Ofatumumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced promising pre-clinical data on its proprietary drug candidate MOR208. |
